{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RAS+Pathway", "query": { "condition": "RAS Pathway" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 21, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RAS+Pathway&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T16:01:46.244Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07549646", "title": "24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ras/MAPK Pathway Vascular Anomalies", "Vascular Anomalies", "Vascular Anomaly" ], "interventions": [ { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Months to 30 Years" }, "enrollment_count": 45, "start_date": "2025-08-27", "completion_date": "2030-08-27", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-07-22T16:01:46.244Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07549646" }, { "nct_id": "NCT04409639", "title": "Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myelomonocytic Leukemia (CMML)" ], "interventions": [ { "name": "Cobimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2021-01-12", "completion_date": "2026-08", "has_results": true, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-07-22T16:01:46.244Z", "location_count": 3, "location_summary": "Portland, Oregon • Salt Lake City, Utah • Seattle, Washington", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04409639" }, { "nct_id": "NCT07121829", "title": "Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Solid Tumor", "Pilocytic Astrocytoma", "Non Small Cell Lung Cancer", "Colorectal Cancer", "Pancreatic Cancer", "MAP Kinase Family Gene Mutation", "RAS Mutation", "RAF Mutation", "MEK Mutation" ], "interventions": [ { "name": "Tovorafenib", "type": "DRUG" }, { "name": "Tovorafenib Drug: Pimasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Day One Biopharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 44, "start_date": "2022-05-02", "completion_date": "2024-12-18", "has_results": false, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-07-22T16:01:46.244Z", "location_count": 8, "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07121829" }, { "nct_id": "NCT04198818", "title": "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Tumors", "Melanoma", "Non-Small-Cell Lung Cancer", "Erdheim-Chester Disease", "Other RAS/RAF/MEK/ERK Mutated Tumors" ], "interventions": [ { "name": "HH2710", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Haihe Biopharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2020-01-07", "completion_date": "2023-03-31", "has_results": true, "last_update_posted_date": "2024-07-19", "last_synced_at": "2026-07-22T16:01:46.244Z", "location_count": 2, "location_summary": "Lafayette, Indiana • Detroit, Michigan", "locations": [ { "city": "Lafayette", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04198818" }, { "nct_id": "NCT06270082", "title": "Study of IK-595 in RAS- or RAF-altered Advanced Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "Pancreatic Cancer", "Malignant Melanoma", "Ras (Kras or Nras) Gene Mutation", "BRAF Gene Mutation", "CRAF Gene Mutation", "Non-Small Cell Lung Carcinoma", "Thyroid Carcinoma", "Gliomas, Malignant" ], "interventions": [ { "name": "IK-595", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ikena Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2023-12-18", "completion_date": "2025-09-08", "has_results": false, "last_update_posted_date": "2025-09-19", "last_synced_at": "2026-07-22T16:01:46.244Z", "location_count": 15, "location_summary": "Duarte, California • Orange, California • Denver, Colorado + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06270082" }, { "nct_id": "NCT00098254", "title": "BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Carcinoma" ], "interventions": [ { "name": "BAY 43-9006 (Sorafenib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2004-12", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2012-05-02", "last_synced_at": "2026-07-22T16:01:46.244Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098254" }, { "nct_id": "NCT03429803", "title": "DAY101 In Gliomas and Other Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Low-grade Glioma" ], "interventions": [ { "name": "DAY101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karen D. Wright, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 44, "start_date": "2018-02-27", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-07-22T16:01:46.244Z", "location_count": 15, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03429803" }, { "nct_id": "NCT03162627", "title": "Selumetinib and Olaparib in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Neoplasm of Breast", "Malignant Neoplasms of Digestive Organs", "Malignant Neoplasms of Female Genital Organs", "Malignant Neoplasms of Male Genital Organs", "Malignant Neoplasms of Thyroid and Other Endocrine Glands" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2017-08-04", "completion_date": "2026-08-30", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-07-22T16:01:46.244Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03162627" }, { "nct_id": "NCT06326411", "title": "A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Oncology", "MEK Mutation", "RAF Gene Mutation", "Ras (KRAS or NRAS) Gene Mutation", "Melanoma", "NSCLC", "Glioma", "Solid Tumor, Adult", "MAPK Pathway Gene Mutation" ], "interventions": [ { "name": "NST-628", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nested Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2024-04-09", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-07-22T16:01:46.244Z", "location_count": 17, "location_summary": "San Francisco, California • Westwood, Los Angeles, California • Denver, Colorado + 11 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Westwood, Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06326411" }, { "nct_id": "NCT04888936", "title": "Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Costello Syndrome", "Noonan Syndrome", "Cardiofaciocutaneous Syndrome", "Legius Syndrome", "Capillary Arteriovenous Malformation Syndrome", "RASopathy" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Month", "maximum_age": "99 Years", "sex": "ALL", "summary": "1 Month to 99 Years" }, "enrollment_count": 500, "start_date": "2022-04-25", "completion_date": "2035-01-31", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-07-22T16:01:46.244Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Rockville, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04888936" } ] }